A t(1;9) translocation involving as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm.
作者信息
Gutiérrez-Abril Jesús, Santamaría Iñigo, Pitiot Ana S, Gutiérrez-Fernández Ana, Alvarez-Eguiluz Ángel, Vicente José M, Sanzo Carmen, González-Muñiz Soledad, Balbín Milagros, Puente Xose S
机构信息
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Asturias, Spain.
Laboratorio de Oncología Molecular, Laboratorio de Medicina, Instituto Universitario de Oncología (IUOPA), Hospital Universitario Central de Asturias, Asturias, Spain.
出版信息
Haematologica. 2017 Dec;102(12):e510-e513. doi: 10.3324/haematol.2017.176693. Epub 2017 Sep 21.
Abstract
摘要
相似文献
1
A t(1;9) translocation involving as a novel mechanism in unclassifiable chronic myeloproliferative neoplasm.一种涉及t(1;9)易位的情况作为不可分类的慢性骨髓增殖性肿瘤的一种新机制。
Haematologica. 2017 Dec;102(12):e510-e513. doi: 10.3324/haematol.2017.176693. Epub 2017 Sep 21.
2
Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.髓系肿瘤中的克隆性突变与形态发生性突变：U2AF1、TET2、CSF3R和JAK2“共突变”的骨髓增殖性肿瘤的时间顺序观察提示突变的层级顺序及对激酶抑制剂治疗反应的潜在预测价值。
Leuk Lymphoma. 2018 Aug;59(8):1994-1997. doi: 10.1080/10428194.2017.1406087. Epub 2017 Dec 3.
3
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.CSF3R T618I 突变导致小鼠发生致命性中性粒细胞肿瘤，对治疗性 JAK 抑制有反应。
Blood. 2013 Nov 21;122(22):3628-31. doi: 10.1182/blood-2013-06-509976. Epub 2013 Sep 30.
4
De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.与骨髓增殖性肿瘤转化为非典型慢性粒细胞白血病相关的新发CSF3R突变
Ann Hematol. 2015 Jul;94(7):1255-6. doi: 10.1007/s00277-015-2366-3. Epub 2015 Apr 14.
5
Durable remission with ruxolitinib in a chronic neutrophilic leukemia patient harboring a truncation and membrane proximal CSF3R compound mutation.鲁索替尼使一名患有截短型和膜近端CSF3R复合突变的慢性嗜中性粒细胞白血病患者实现持久缓解。
Ann Hematol. 2021 Feb;100(2):581-584. doi: 10.1007/s00277-020-04152-w. Epub 2020 Jun 23.
6
[New mutations in myeloproliferative neoplasms; 2014 update].[骨髓增殖性肿瘤中的新突变；2014年更新]
Rinsho Ketsueki. 2014 Oct;55(10):1833-40.
7
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq.通过RNA测序在一名患有t(1;9)(p34;q34)的非典型慢性髓性白血病患者中鉴定出一种新型CSF3R-SPTAN1融合基因。
Cancer Genet. 2017 Oct;216-217:16-19. doi: 10.1016/j.cancergen.2017.05.002. Epub 2017 May 24.
8
A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene.一种伴有涉及JAK2基因的t(8;9)(p22;p24)易位的骨髓增殖性肿瘤。
Blood. 2013 Aug 8;122(6):861. doi: 10.1182/blood-2013-03-487348.
9
CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8; 21).儿童髓系疾病中的CSF3R和CALR突变以及CSF3R突变与易位（包括t(8;21)）的关联
Br J Haematol. 2015 Aug;170(3):391-7. doi: 10.1111/bjh.13439. Epub 2015 Apr 9.
10
Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.伊马替尼治疗成功作为非典型骨髓增殖性肿瘤移植的桥梁。
Curr Res Transl Med. 2019 Nov;67(4):149-151. doi: 10.1016/j.retram.2019.04.003. Epub 2019 May 30.
本文引用的文献
1
Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent mutations in chronic neutrophilic leukemia.芦可替尼是一种有效的JAK1/JAK2抑制剂，可使慢性嗜中性粒细胞白血病中并发突变的等位基因负担暂时降低。
Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16.
2
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
3
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.鲁索替尼治疗CSF3R T618突变型慢性中性粒细胞白血病的临床反应。
Ann Hematol. 2016 Jun;95(7):1197-200. doi: 10.1007/s00277-016-2664-4. Epub 2016 Apr 11.
4
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.ASXL1 突变在 CSF3R 突变的慢性中性粒细胞白血病中频繁发生且具有预后不良影响。
Am J Hematol. 2015 Jul;90(7):653-6. doi: 10.1002/ajh.24031.
5
LUMPY: a probabilistic framework for structural variant discovery.LUMPY：一种用于结构变异发现的概率框架。
Genome Biol. 2014 Jun 26;15(6):R84. doi: 10.1186/gb-2014-15-6-r84.
6
Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition. alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition.
剪接变异、截断的 GCSF 受体促进白血病发生特性和对 JAK 抑制的敏感性。
Leukemia. 2014 May;28(5):1041-51. doi: 10.1038/leu.2013.321. Epub 2013 Oct 30.
7
The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.慢性中性粒细胞白血病和非典型 CML 的新遗传学：对诊断和治疗的影响。
Blood. 2013 Sep 5;122(10):1707-11. doi: 10.1182/blood-2013-05-500959. Epub 2013 Jul 29.
8
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.致癌性 CSF3R 突变在慢性中性粒细胞白血病和非典型 CML 中的作用。
N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.
9
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.CSF3R T618I 是慢性中性粒细胞白血病中一种高度普遍且特异性的突变。
Leukemia. 2013 Sep;27(9):1870-3. doi: 10.1038/leu.2013.122. Epub 2013 Apr 22.
10
Fast and accurate long-read alignment with Burrows-Wheeler transform.基于 Burrows-Wheeler 变换的快速准确长读比对。
Bioinformatics. 2010 Mar 1;26(5):589-95. doi: 10.1093/bioinformatics/btp698. Epub 2010 Jan 15.
Zotero 插件